Table 1.
2012-2017 Influenza seasons | |||
---|---|---|---|
Baseline cohorts | Control group: Vaccinated patients ≥50 y without joint injection | Major joint CS injection group |
|
Unvaccinated | Vaccinated | ||
n | 43,236 | 10,264 | 4804 |
Age (y), mean ± SDb | 67.4±10.4 | 62.4±15.8 | 65.9±14.3 |
% under 65 yb | 42.4 | 56.5 | 41.9 |
Sex | 61.9 | ||
% femaleb | 53.1 | 64.1 | |
BMI (kg/m2),b mean ± SD | 27.6±7.5 | 31.5±8.1 | 31.4±7.3 |
Comorbidities, % | |||
Diabetes | 12.50 | 9.30 | 12.82 |
COPD | 4.96 | 4.74 | 5.47 |
Rheumatoid arthritisb | 1.98 | 4.19 | 4.27 |
PMR/GA/Lupus/ScDb | 1.10 | 1.57 | 1.72 |
Chemotherapy | 0.97 | 0.57 | 0.54 |
Crohn's/UC | 0.92 | 0.84 | 0.87 |
CLL | 0.62 | 0.25 | 0.44 |
Myeloma | 0.22 | 0.19 | 0.17 |
Patients with influenza diagnosis, 2012-2017 influenza seasons | |||
---|---|---|---|
Patients with influenza | Control group: Vaccinated patients ≥50 y without joint injection | Major joint CS injection group |
|
Unvaccinated | Vaccinated | ||
n (% baseline) | 466 (1.08) | 175 (1.70) | 79 (1.64) |
Age (y), mean ± SD | 66.8±10.7 | 61.0±17.8 | 61.3±16.4c |
% under 65 y | 46.8% | 62.8% | 58.2% |
Sex | 67.1 | ||
% female | 53.1 | 75.4 | |
BMI (kg/m2), mean ± SD | 29.4±9.7 | 28.4±7.1 | 28.0±6.4 |
Comorbidities, n (%) | |||
Diabetes | 91 (19.53)c | 20 (11.42) | 14 (17.72) |
COPD | 62 (20.24)c | 16 (9.14)c | 9 (11.39)c |
Rheumatoid arthritis | 9 (2.02) | 6 (3.42) | 2 (2.53) |
PMR/GA/Lupus/ScD | 11 (2.36) | 2 (1.14) | 3 (3.79) |
Chemotherapy | 8 (1.72) | 1 (0.57) | 0 |
Crohn/UC | 7 (1.50) | 6 (3.43) | 2 (2.53) |
CLL | 7 (1.50) | 2 (1.14) | 1 (1.26) |
Myeloma | 0 | 3 (1.71) | 0 |
CLL = chronic lymphocytic leukemia; COPD = chronic obstructive pulmonary disease; CS = corticosteroid; GA = giant cell arteritis; PMR = polymyalgia rheumatica; ScD = scleroderma; UC = ulcerative colitis.
P<.05 between-group differences.
P<.05 difference compared with respective baseline cohort.